Quick Answer
Royalty Pharma plc reported Operating Income Loss of $1.56 billion for the year ending 2025.
- Royalty Pharma plc showed an increase of +20.7% in Operating Income Loss from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $327.86 million | Q3 2019: $532.50 million | Q1 2020: $361.43 million | Q2 2020: $409.35 million | Q3 2020: $510.57 million | Q1 2021: $229.30 million | Q2 2021: $744.95 million | Q3 2021: $303.05 million | Q1 2022: $219.72 million | Q2 2022: $377.79 million | Q3 2022: $192.21 million | Q1 2023: $478.97 million | Q2 2023: $248.84 million | Q3 2023: $151.44 million | Q1 2024: -$73.77 million | Q2 2024: $269.63 million | Q3 2024: $735.07 million | Q1 2025: $534.18 million | Q2 2025: $209.80 million | Q3 2025: $427.16 million.
- Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Operating Income Loss has grown by 14.3%.
- Historical annual values: Fiscal year 2025: $1.56 billion | Fiscal year 2024: $1.29 billion | Fiscal year 2023: $1.49 billion | Fiscal year 2022: $307.07 million | Fiscal year 2021: $1.43 billion | Fiscal year 2020: $1.60 billion | Fiscal year 2019: $2.62 billion | Fiscal year 2018: $1.36 billion.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: